Views & Analysis Gene editing: beyond the hype Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities.
Partner Content Partner Content Targeting Solid & Liquid Malignancies with the Same CAR Cell and Gene Therapy
Oncology Hernexeos and what’s next, with Vicky Brown At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent approval for Hernexeos in NSCLC.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
